导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.91% | 1509/4773 |
| 近一周 | -1.41% | 2136/5465 |
| 近一月 | -8.37% | 4917/5421 |
| 近一季 | -19.82% | 4914/5231 |
| 近半年 | 2.36% | 1058/4920 |
| 近一年 | 7.97% | 1396/4394 |
| 近两年 | 139.52% | 314/2954 |
| 近三年 | 91.76% | 201/2253 |
| 成立以来 | 115.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.80% 3419/4961 |
41.30% 754/5312 |
- - |
- - |
| 2025 | 62.66% 180/4813 |
-1.99% 2828/3635 |
5.32% 610/4076 |
58.50% 147/4524 |
-0.58% 2546/4813 |
| 2024 | 20.54% 459/3463 |
-2.48% 1368/2808 |
-5.64% 1768/3014 |
32.13% 102/3129 |
-0.85% 1532/3463 |
| 2023 | -22.51% 1931/2656 |
-1.60% 1884/2280 |
-8.36% 1989/2385 |
-8.88% 1743/2515 |
-5.68% 1457/2655 |
| 2022 | -27.81% 1510/2207 |
-21.25% 1609/1919 |
8.48% 360/2016 |
-18.46% 1712/2113 |
3.63% 665/2208 |
| 2021 | 20.13% 185/1822 |
-4.72% 883/1255 |
32.02% 35/1330 |
-5.47% 809/1466 |
1.02% 1021/1822 |
| 2020 | - - |
- - |
- - |
9.56% 641/1164 |
18.88% 86/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 招商创业板大盘ETF VS. 长安沪深300非周期A(740101) |